Leflunomide Medac

Leflunomide, the active ingredient in Leflunomide Medac, is an immunomodulatory agent presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce joint inflammation and slow disease progression.

GNH USA supplies Leflunomide Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that targets autoimmune arthritis pathways.

- Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage. - Psoriatic arthritis: improves joint symptoms and may benefit associated skin lesions. - Autoimmune arthritis: provides long‑term disease‑modifying effects to slow progression of chronic inflammatory joint disease.

Leflunomide may cause a range of adverse reactions.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Elevated liver enzymes: mild transaminase rise. - Hypertension: increase in blood pressure readings. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Serious infections: opportunistic or bacterial infections. - Interstitial lung disease: pulmonary inflammation and fibrosis. - Bone‑marrow suppression: neutropenia or anemia. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Teratogenicity: fetal harm if exposure occurs during pregnancy.

Before initiating therapy, several safety considerations are essential.

- Pregnancy contraindication: Leflunomide is category X; avoid use in pregnant women. - Liver monitoring: obtain baseline liver function tests and repeat periodically. - Blood pressure: monitor regularly, especially in patients with hypertension. - Hematology: check complete blood counts to detect bone‑marrow suppression. - Infection risk: postpone treatment in active severe infections. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Leflunomide can affect the pharmacokinetics or safety of several medicines.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: additive toxicity, especially hepatic. - Cholesterol‑binding resins (e.g., cholestyramine): reduce Leflunomide exposure. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Azathioprine: potential for enhanced bone‑marrow suppression. - Cyclosporine: may increase plasma concentrations of Leflunomide. - Statins: possible increase in statin levels, monitor for myopathy. - NSAIDs: may exacerbate gastrointestinal side effects.